Advertisement

Picture EBD Group BioPharm Amercia 2022 Boston 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from the Benelux countries Belgium, Luxembourg and The Netherlands or involving organisations from these countries.

Total search results: 1642 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Abound Bio–Galapagos: investment, 202206 acquisition $14m in cash of AboundBio by Galapagos 2022-06-21
CellPoint–Galapagos: investment, 202206 acquisition in cash €125m upfront + €100m milestones of CellPoint by Galapagos 2022-06-21
JnJ–Evotec: drug discovery services, 202206– collab discover novel mode of action drugs using TargetAlloMod platforms for Janssen Pharmaceutica 2022-06-14
ImCheck Therapeutics–SEVERAL: investment, 202206 financing round Series C €80m co-led by new investors Earlybird + Andera Partners 2022-06-13
Forbion–SEVERAL: investment, 202206 first close €470m of Forbion Growth Opportunities Fund II with target size of €600m hard cap 2022-06-09
Ariceum Therapeutics–Bellevue: investment, 202206 financing round Series A totalling €25m incl co-investor Pureos Bioventures 2022-06-08
Ariceum Therapeutics–EQT: investment, 202206 financing round Series A totalling €25m incl co-founding + co-lead investor EQT Life Sciences 2022-06-08
Ariceum Therapeutics–SEVERAL: investment, 202206 financing round Series A €25m co-led by HealthCap + EQT Life Sciences 2022-06-08
Frame Cancer Therapeutics–CureVac: investment, 202206 acquisition in shares €32m with €16m upfront + €16m milestones 2022-06-08
CimCure–Intravacc: cancer vaccine, 202206 collab existent developm + production of lead compound of CimCure 2022-06-07
CimCure–PERSON: investment, 202206 seed financing round totalling €5m incl co-investor investment vehicle of Tom Würdinger 2022-06-07
CimCure–Positron Ventures: investment, 202206 seed financing round totalling €5m incl lead investor Positron Ventures 2022-06-07
CimCure–SEVERAL: investment, 202206 seed financing round €5m led by Positron Ventures 2022-06-07
ImmunOs Therapeutics–Gimv: investment, 202206 financing round Series B totalling $74m incl new + co-lead investor Gimv 2022-06-07
ImmunOs Therapeutics–SEVERAL: investment, 202206 financing round Series B $74m led by Samsara BioCapital + Lightspeed VP + Gimv 2022-06-07
Vizgen–SEVERAL: investment, 202206 financing round Series C $85.2m co-led by Blue Water Life Science + ARCH Venture Partners 2022-06-03
Vizgen–Sofina: investment, 202206 financing round Series C totalling $85.2m incl co-investor Sofina 2022-06-03
BMS–Immatics: cancer immunotherapy, 202201– collab strategic alliance expansion $60m upfront + $700 milestones per programme using ACTallo platform 2022-06-02
Firmenich–DSM: investment, 202205– merger with former DMS owners holding 65.5% + Firmenich owners receiving 34.5% plus €3.5b in cash ANNOUNCED 2022-05-31
Minoryx–Columbus Venture Partners: investment, 202205 financing round Series C incl co-lead investor Columbus Venture Partners 2022-05-31
Minoryx–Fund+: investment, 202205 financing round Series C incl existing + co-investor Fund+ 2022-05-31
Minoryx–SEVERAL: credit, 202205 complementary bank debt to Series C financing round (both tog totalling €51m) 2022-05-31
Minoryx–SEVERAL: investment, 202205 financing round Series C (incl complementary bank totalling €51m) led by Columbus VP + Caixa Capital Risc 2022-05-31
Minoryx–Spain (govt): investment, 202205 financing round Series C incl new + co-investor CDTI Innvierte 2022-05-31
Minoryx–Ysios Capital: investment, 202205 financing round Series C incl existing + co-investor Ysios Capital 2022-05-31
Repertoire Genesis–Eurofins: investment, 202205 acquisition of majority stake by Eurofins Scientific 2022-05-31
CureVac–myNEO: drug target discovery, 202205– collab research + option agreem antigen targets for mRNA cancer vaccines 2022-05-25
Alithea Genomics–Novalis Biotech: investment, 202205 seed financing round totalling CHF1m incl lead investor Novalis Biotech Acceleration Fund 2022-05-24
Alithea Genomics–SEVERAL: investment, 202205 seed financing round CHF1m led by Novalis Biotech Acceleration Fund 2022-05-24
Allergios–NLC Ventures: investment, 202205 existent shareholder NLC 2022-05-23
Allergios–SEVERAL: investment, 202205 seed financing round 2022-05-23
Synexa Life Sciences–Gilde Investment: investment, 202205 existent Synexa is backed by Gilde Healthcare 2022-05-19
Syrinx Bioanalytics–Synexa Life Sciences: investment, 202205 acquisition of Syrinx Bioanalytics Oy by Synexa 2022-05-19
Apollo Global Management–Sofinnova: life science financing, 202205– strategic partnership incl investm in Sofinnova Partners + up to $1b capital 2022-05-16
Sofinnova–Apollo Global Management: investment, 202205– acquisition of minority equity interest in Sofinnova Partners as part of strategic partnership 2022-05-16
Sofinnova–Apollo Global Management: investment, 202205– commitment of up to $1b managed capital to Sofinnova Partners investment funds by Apollo 2022-05-16
BLIRT–Qiagen: investment, 202205 acquisition 96% ownership stake by Qiagen 2022-05-11
Domain Therapeutics–SEVERAL: investment, 202205 financing round Series A €39m co-led by Panacea Venture + CTI Life Sciences + 3B Future Health Fund 2022-05-10
Domain Therapeutics–Theodorus: investment, 202205 financing round Series A totalling €39m incl co-investor Theodorus 2022-05-10
Hemispherian–Meneldor: investment, 202205 seed financing round totalling NOK12.5m ($1.4m) incl lead investor Meneldor 2022-05-03
Hemispherian–SEVERAL: investment, 202205 seed financing round NOK12.5m ($1.4m) led by Meneldor with Norwegian + American investors 2022-05-03
Tubulis–Fund+: investment, 202205 financing round Series B totalling €60m incl new + co-investor Fund+ 2022-05-03
Tubulis–SEVERAL: investment, 202205 financing round Series B €60m led by new investor Andera Partners 2022-05-03
Stentit–SEVERAL: investment, 202204 seed financing round €1.8m from Nextgen Ventures + BOM + Ten Cate Investment Company 2022-04-25
NLC Ventures–Charles River: drug discovery services, 202204– collab MoU supply early drug discovery + developm services for NLC portfolio companies 2022-04-20
Monkeys not Donkeys–Quality by Design (QbD): investment, 202204 acquisition of MnD by QbD 2022-04-13
Affimed–SEVERAL: investment, 202204 public offering $90m+$13.5m with 22.5m+3.375m common shares at $4/share PRICED 2022-04-12
Labster–Sofina: investment, 202204 financing round Series C 2nd tranche totalling $47m incl new investor Sofina Group 2022-04-04
V-Bio Ventures–SEVERAL: investment, 202203 final closing with additional €32m of V-Bio Ventures Fund 2 bringing total fund size to €110m 2022-03-31
Axa–Canary Wharf Group: real estate, 202203– collab joint venture of Kadans Science Partner + CWG to built wet lab buliding in Canary Wharf London 2022-03-30
BioStrand–ImmunoPrecise: investment, 202203– acquistion merger of BioStrand for up to €32m with €1.5m in cash upfront + €18m upfront in shares by IPA 2022-03-29
Core Biogenesis–Blue Horizon Ventures: investment, 202203 financing round Series A totalling €10m incl new + co-lead investor Blue Horizon Ventures 2022-03-29
Core Biogenesis–SEVERAL: investment, 202203 financing round Series A €10m led by XAnge + Blue Horizon Ventures 2022-03-29
Argenx–SEVERAL: investment, 202203 EU + GB private placment €213.6m with 782.3k ordinary shares at €273.10/share 2022-03-22
Argenx–SEVERAL: investment, 202203 US public offering $465.3m+$105m with 1.9m ADSs at $300/ADS 2022-03-22
Gilde Investment–SEVERAL: investment, 202203 first + final close of €517m Gilde Healthcare Private Equity IV fund 2022-03-16
Precirix–SEVERAL: investment, 202203 financing round Series B €80 co-led by new investors Inkef Capital + Jeito Capital + Forbion 2022-03-16
Qbic–SEVERAL: investment, 202203 first close €49m of Qbic III fund 2022-03-16
Ayoxxa–Prosnav Capital: investment, 202203 financing round providing runway for 3-5 years incl new + lead investor Prosnav Capital 2022-03-14
Ayoxxa–SEVERAL: investment, 202203 financing round providing runway for 3-5 years led by new investor Prosnav Capital 2022-03-14
Roche–Scenic Biotech: drugs targeting genetic modifiers, 202203 collab multi-year multi-target existent with Genentech 2022-03-10
Scenic Biotech–ABP (NL): investment, 202203 financing round Series A totalling €28m incl existing + co-investor Inkef Capital 2022-03-10
Scenic Biotech–BioGeneration Ventures: investment, 202203 financing round Series A totalling €28m incl existing + co-investor BioGeneration Ventures 2022-03-10
Scenic Biotech–BioMedPartners: investment, 202203 financing round Series A totalling €28m incl new + co-lead investor BioMedPartners 2022-03-10
Scenic Biotech–Eir Ventures: investment, 202203 financing round Series A totalling €28m incl new + co-lead investor Eir Ventures 2022-03-10
Scenic Biotech–SEVERAL: investment, 202203 financing round Series A €28m co-led by Eir Ventures + BioMedPartners + Vesalius Biocapital 2022-03-10
Scenic Biotech–Univ Oxford: investment, 202203 financing round Series A totalling €28m incl existing + co-investor Oxford Science Enterprises 2022-03-10
Scenic Biotech–Vesalius Biocapital: investment, 202203 financing round Series A totalling €28m incl new + co-lead investor Vesalius Biocapital 2022-03-10
Eurazeo–SEVERAL: investment, 202203 first closing €160m of Kurma Partners Growth Opportunities Fund targeting €250m 2022-03-07
In Ovo–ABN AMRO: investment, 202203 financing round totalling €34m incl new investor ABN AMRO 2022-03-01
In Ovo–ECBF: investment, 202203 financing round totalling €34m incl new investor ECBF 2022-03-01
In Ovo–Evonik: investment, 202203 financing round totalling €34m incl existing investor Evonik 2022-03-01
In Ovo–SEVERAL: investment, 202203 financing round €34m with ECBF + ABN AMRO et al 2022-03-01
Syndesi Therapeutics–AbbVie: investment, 202203 acquisition of Syndesi for $130m upfront + $870m milestones 2022-03-01
Aphea.Bio–ECBF: investment, 202202 existent investment of ECBF 2022-02-23
TargED Biopharmaceuticals–SEVERAL: investment, 202202 financing round Series A €39m 2022-02-22
SpliceBio–SEVERAL: investment, 202202 financing round Series A €50m co-led by UCB Ventures + Ysios Capital 2022-02-16
Aboleris Pharma–Newton Biocapital: investment, 202202 existent investment of NBC I fund 2022-02-15
ChromaCure–Newton Biocapital: investment, 202202 existent investment of NBC I fund 2022-02-15
DeuterOncology–Newton Biocapital: investment, 202202 existent investment of NBC I fund 2022-02-15
Epics Therapeutics–Newton Biocapital: investment, 202202 existent investment of NBC I fund 2022-02-15
Newton Biocapital–SEVERAL: investment, 202202 1st closing NBC II Fund at €50m with target size of €150m 2022-02-15
NMD Pharma–ABP (NL): investment, 202202 financing round totalling €35m incl existing + co-investor Inkef Capital 2022-02-15
NMD Pharma–SEVERAL: investment, 202202 financing round €35m led by new investor Jeito Capital + incl existing investors 2022-02-15
Perseus Proteomics–Newton Biocapital: investment, before 202202 former pre-IPO early-exit investment of NBC I fund 2022-02-15
Sequana Medical –Newton Biocapital: investment, before 202202 former pre-IPO early-exit investment of NBC I fund 2022-02-15
Apmonia Therapeutics–SEVERAL: investment, 202202 funding round €4m incl equity investments + Bpifrance loans + governmental/regional grants 2022-02-10
Celeris Therapeutics–i&i Biotech Fund: investment, 202202 seed financing round totalling $4.4m incl new + co-lead investor i&i Biotech Fund 2022-02-10
Celeris Therapeutics–SEVERAL: investment, 202202 seed financing round $4.4m led by Pace Ventures Enigma + i&i Biotech Fund + Apex Ventures 2022-02-10
Elicit Plant–ECBF: investment, 202202 equity component €na of €16m funding round incl co-investor ECBF 2022-02-07
Elicit Plant–SEVERAL: investment, 202202 equity component €na led by Sofinnova Partners as part of funding round totalling €16m 2022-02-07
Merck (DE)–eTheRNA: mRNA technology, 202202– collab research using eTheRNA’s mRNA + LNP technologies to evaluate therapeutic feasibility 2022-02-03
Weriol Group–BRAIN Biotech: investment, 202202 acquisition of 62% of Breatec/Comix for €3.7m upfront + option to acquire remaining shares until 2027Q1 2022-02-03
Pharvaris–BRAIN Biotech: drug discovery services, 202202–202307 collab extension 9 months RnD bradykinin-B2-receptor antagonists Analyticon Discovery 2022-02-01
Mainz Biomed–SEVERAL: investment, 202201 public follow-on offering $22.5m+$3.375m with 1.725m+225k common shares at $15/share 2022-01-28
Leyden Laboratories–SEVERAL: investment, 202201 financing round Series B $140m led by Casdin Capital + GV 2022-01-25
Zogenix–UCB: investment, 202201– cash tender offer $1.76b at $26/share plus $135.7m CVR milestones ANNOUNCED 2022-01-19
Leyden Laboratories–JnJ: therapeutic antibody, 202201– ww excl license to develop + commcercialise CR9114 for mucosal administration from Janssen 2022-01-18
Rockefeller Univ–Lumicks: microscope, 202201 supply of Quadrupole C-Trap system to lab of Prof Michael O’Donnell 2022-01-12
Creoptix–Spectris: investment, 202201 acquisition of Creoptix AG by Malvern Panalytical 2022-01-11
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  next pagenext page



Advertisement

Picture [iito] Männer Ballett 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group BIO-Europe 2022 Leipzig 650x300px

» top